Structural and functional insights into the HIV-1 maturation inhibitor binding pocket. 2012

Kayoko Waki, and Stewart R Durell, and Ferri Soheilian, and Kunio Nagashima, and Scott L Butler, and Eric O Freed
Virus-Cell Interaction Section, HIV Drug Resistance Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, Maryland, United States of America.

Processing of the Gag precursor protein by the viral protease during particle release triggers virion maturation, an essential step in the virus replication cycle. The first-in-class HIV-1 maturation inhibitor dimethylsuccinyl betulinic acid [PA-457 or bevirimat (BVM)] blocks HIV-1 maturation by inhibiting the cleavage of the capsid-spacer peptide 1 (CA-SP1) intermediate to mature CA. A structurally distinct molecule, PF-46396, was recently reported to have a similar mode of action to that of BVM. Because of the structural dissimilarity between BVM and PF-46396, we hypothesized that the two compounds might interact differentially with the putative maturation inhibitor-binding pocket in Gag. To test this hypothesis, PF-46396 resistance was selected for in vitro. Resistance mutations were identified in three regions of Gag: around the CA-SP1 cleavage site where BVM resistance maps, at CA amino acid 201, and in the CA major homology region (MHR). The MHR mutants are profoundly PF-46396-dependent in Gag assembly and release and virus replication. The severe defect exhibited by the inhibitor-dependent MHR mutants in the absence of the compound is also corrected by a second-site compensatory change far downstream in SP1, suggesting structural and functional cross-talk between the HIV-1 CA MHR and SP1. When PF-46396 and BVM were both present in infected cells they exhibited mutually antagonistic behavior. Together, these results identify Gag residues that line the maturation inhibitor-binding pocket and suggest that BVM and PF-46396 interact differentially with this putative pocket. These findings provide novel insights into the structure-function relationship between the CA MHR and SP1, two domains of Gag that are critical to both assembly and maturation. The highly conserved nature of the MHR across all orthoretroviridae suggests that these findings will be broadly relevant to retroviral assembly. Finally, the results presented here provide a framework for increased structural understanding of HIV-1 maturation inhibitor activity.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013386 Succinates Derivatives of SUCCINIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain a 1,4-carboxy terminated aliphatic structure. Succinic Acids,Acids, Succinic
D014315 Triterpenes A class of terpenes (the general formula C30H48) formed by the condensation of six isoprene units, equivalent to three terpene units. Triterpene,Triterpenoid,Triterpenoids
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D054301 gag Gene Products, Human Immunodeficiency Virus Proteins encoded by the GAG GENE of the HUMAN IMMUNODEFICIENCY VIRUS. gag Gene Products, HIV,gag Proteins, Human Immunodeficiency Virus
D059748 Proteolysis Cleavage of proteins into smaller peptides or amino acids either by PROTEASES or non-enzymatically (e.g., Hydrolysis). It does not include Protein Processing, Post-Translational. Protein Degradation,Protein Digestion,Degradation, Protein,Degradations, Protein,Digestion, Protein,Digestions, Protein,Protein Degradations,Protein Digestions,Proteolyses
D019169 Jurkat Cells A CELL LINE derived from human T-CELL LEUKEMIA and used to determine the mechanism of differential susceptibility to anti-cancer drugs and radiation. Cell, Jurkat,Cells, Jurkat,Jurkat Cell

Related Publications

Kayoko Waki, and Stewart R Durell, and Ferri Soheilian, and Kunio Nagashima, and Scott L Butler, and Eric O Freed
February 2013, Journal of the American Chemical Society,
Kayoko Waki, and Stewart R Durell, and Ferri Soheilian, and Kunio Nagashima, and Scott L Butler, and Eric O Freed
March 2023, Nature communications,
Kayoko Waki, and Stewart R Durell, and Ferri Soheilian, and Kunio Nagashima, and Scott L Butler, and Eric O Freed
September 2011, Biochimie,
Kayoko Waki, and Stewart R Durell, and Ferri Soheilian, and Kunio Nagashima, and Scott L Butler, and Eric O Freed
March 2017, Scientific reports,
Kayoko Waki, and Stewart R Durell, and Ferri Soheilian, and Kunio Nagashima, and Scott L Butler, and Eric O Freed
September 2006, Journal of medicinal chemistry,
Kayoko Waki, and Stewart R Durell, and Ferri Soheilian, and Kunio Nagashima, and Scott L Butler, and Eric O Freed
November 2017, Nature communications,
Kayoko Waki, and Stewart R Durell, and Ferri Soheilian, and Kunio Nagashima, and Scott L Butler, and Eric O Freed
January 2018, Frontiers in cellular and infection microbiology,
Kayoko Waki, and Stewart R Durell, and Ferri Soheilian, and Kunio Nagashima, and Scott L Butler, and Eric O Freed
January 2016, Journal of virology,
Kayoko Waki, and Stewart R Durell, and Ferri Soheilian, and Kunio Nagashima, and Scott L Butler, and Eric O Freed
January 2012, PloS one,
Kayoko Waki, and Stewart R Durell, and Ferri Soheilian, and Kunio Nagashima, and Scott L Butler, and Eric O Freed
October 2019, Journal of biomolecular structure & dynamics,
Copied contents to your clipboard!